Genentech R&D Combining Diagnostics With Drugs Throughout The Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
Avastin is one example where the drug’s mechanism of action may be too broad to warrant a companion diagnostic, CEO Levinson says.